Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRN322
MIFTS: 40

Coronavirus Infectious Disease

Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Coronavirus Infectious Disease

About this section

MalaCards integrated aliases for Coronavirus Infectious Disease:

Name: Coronavirus Infectious Disease 12 17
Coronavirus Infection 15

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080599
Sources

Summaries for Coronavirus Infectious Disease

About this section
Disease Ontology : 12 A viral infectious disease that has material basis in Coronavirus.

MalaCards based summary : Coronavirus Infectious Disease, also known as coronavirus infection, is related to middle east respiratory syndrome and common cold. An important gene associated with Coronavirus Infectious Disease is ACE2 (Angiotensin I Converting Enzyme 2), and among its related pathways/superpathways are Measles and Tuberculosis. The drugs Bromhexine and Oseltamivir have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and t cells, and related phenotype is immune system.

Sources

Related Diseases for Coronavirus Infectious Disease

About this section

Diseases related to Coronavirus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 574)
# Related Disease Score Top Affiliating Genes
1 middle east respiratory syndrome 32.8 TMPRSS2 SH2D3C SH2D3A SCARA3 PPP1CA IFNB1
2 common cold 31.1 IL6 CD4 CCR6
3 encephalitis 31.0 PPP1CA IL6 IFNB1 IFNA1 CLEC4M
4 perinatal necrotizing enterocolitis 30.9 IL6 CRP CCR6
5 respiratory failure 30.8 SERPINA3 IL6 H2AC18 CRP CD4 CCR6
6 bronchopneumonia 30.8 SERPINA3 IL6 CRP CD8A CD4
7 lung disease 30.8 SERPINA3 MBL2 IL6 CRP CD8A ACE
8 bronchiolitis 30.8 IL6 IFNA1 CRP
9 vasculitis 30.7 SERPINA3 MBL2 IL6 CRP
10 pneumonia 30.7 MBL2 IL6 IFNB1 IFNA1 CRP CD8A
11 dysentery 30.7 IL6 H2AC18 CRP CD4 CCR6
12 demyelinating disease 30.6 SERPINA3 IL6 IFNB1 IFNA1 H2AC18 CD8A
13 croup 30.6 SH2D3A CRP ACE2
14 purpura 30.6 IL6 CRP ACE
15 thrombocytopenia due to platelet alloimmunization 30.6 CD8A CD4 CCR6
16 peripheral vascular disease 30.6 IL6 H2AC18 CRP ACE
17 covid-19 30.5 TMPRSS2 IL6 DPP4 CRP CD8A ACE2
18 background diabetic retinopathy 30.5 IL6 CRP ACE
19 neutropenia 30.5 MBL2 IL6 IFNA1 CRP
20 vascular disease 30.4 IL6 CRP CD4 ACE2 ACE
21 severe combined immunodeficiency 30.4 IL6 IFNB1 H2AC18 DPP4 CD4 CCR6
22 viral pneumonia 30.4 IL6 IFNB1 CRP CD8A CD4 CCR6
23 autoimmune disease 30.4 MBL2 IL6 IFNB1 IFNA1 DPP4 CRP
24 chronic kidney disease 30.4 SERPINA3 IL6 CRP ACE2 ACE
25 sleep disorder 30.3 IL6 CRP ACE
26 lipid metabolism disorder 30.3 IL6 H2AC18 CRP ACE
27 proteasome-associated autoinflammatory syndrome 1 30.3 IL6 IFNA1 CRP
28 orchitis 30.3 IL6 H2AC18 CRP CD8A CD4
29 kidney disease 30.3 SERPINA3 IL6 DPP4 CRP ACE2 ACE
30 cerebrovascular disease 30.2 SERPINA3 IL6 CRP ACE
31 viral encephalitis 30.1 IL6 IFNB1 IFNA1 CD8A CD4 CCR6
32 bacterial pneumonia 30.0 SERPINA3 IL6 H2AC18 CRP CD8A CD4
33 immune deficiency disease 30.0 SERPINA3 MBL2 IL6 IFNB1 IFNA1 H2AC18
34 severe acute respiratory syndrome 30.0 TMPRSS2 SH2D3A MBL2 IL6 IFNB1 IFNA1
35 heart disease 29.8 IL6 IFNB1 H2AC18 CRP CD4 ACE2
36 pulmonary disease, chronic obstructive 29.8 SERPINA3 IL6 H2AC18 CRP CD8A CD4
37 exanthem 29.6 SH2D3A IL6 IFNA1 H2AC18 CRP CD8A
38 peripheral nervous system disease 29.5 SERPINA3 IL6 IFNB1 H2AC18 DPP4 CRP
39 oral erosive lichen 10.7 IFNB1 IFNA1
40 cork-handlers' disease 10.7 CD8A CD4
41 progressive relapsing multiple sclerosis 10.6 MBL2 IFNB1 CCR6
42 scabies 10.6 MBL2 CD4 CCR6
43 coccidioidomycosis 10.6 MBL2 CD4 CCR6
44 marburg hemorrhagic fever 10.6 SCARA3 IFNA1 CLEC4M
45 western equine encephalitis 10.6 SH2D3C SH2D3A H2AC18
46 mediastinum teratoma 10.6 CRP ACE
47 uveoparotid fever 10.6 CD8A ACE
48 posterior urethral valves 10.6 IL6 ACE2 ACE
49 ventilation pneumonitis 10.6 CD8A CD4
50 esophageal candidiasis 10.6 CD8A CD4 CCR6

Graphical network of the top 20 diseases related to Coronavirus Infectious Disease:



Diseases related to Coronavirus Infectious Disease
Sources

Symptoms & Phenotypes for Coronavirus Infectious Disease

About this section

MGI Mouse Phenotypes related to Coronavirus Infectious Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.44 ACE ACE2 CCR6 CD4 CD8A CLEC4M
Sources

Drugs & Therapeutics for Coronavirus Infectious Disease

About this section

Drugs for Coronavirus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bromhexine Approved Phase 4 3572-43-8
2
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
3
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
4
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
5
Lopinavir Approved Phase 4 192725-17-0 92727
6
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
7
Linagliptin Approved Phase 4 668270-12-0 10096344
8
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
9
Enoxaparin Approved Phase 4 9005-49-6 772
10
Rivaroxaban Approved Phase 4 366789-02-8
11 Molgramostim Investigational Phase 4 99283-10-0
12 Expectorants Phase 4
13 Immunologic Factors Phase 4
14 Antiviral Agents Phase 4
15 Cytochrome P-450 Enzyme Inhibitors Phase 4
16 Anti-HIV Agents Phase 4
17
protease inhibitors Phase 4
18 HIV Protease Inhibitors Phase 4
19 Anti-Retroviral Agents Phase 4
20 Cytochrome P-450 CYP3A Inhibitors Phase 4
21 Hormones Phase 4
22 Hormone Antagonists Phase 4
23 Insulin, Globin Zinc Phase 4
24 Dipeptidyl-Peptidase IV Inhibitors Phase 4
25 insulin Phase 4
26 Hypoglycemic Agents Phase 4
27 Incretins Phase 4
28 Antithrombins Phase 4
29 Fibrinolytic Agents Phase 4
30 Antithrombin III Phase 4
31 Serine Proteinase Inhibitors Phase 4
32 Factor Xa Inhibitors Phase 4
33 Anticoagulants Phase 4
34 Calcium, Dietary Phase 4
35 calcium heparin Phase 4
36
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
37
Calcium Nutraceutical Phase 4 7440-70-2 271
38
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
39
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
40
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
41 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
42
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
43
Budesonide Approved Phase 3 51333-22-3 63006 5281004
44
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
45
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
46
Pirfenidone Approved, Investigational Phase 3 53179-13-8 40632
47 Siltuximab Approved, Investigational Phase 3 541502-14-1
48
Emtricitabine Approved, Investigational Phase 3 143491-57-0 60877
49
Mefloquine Approved, Investigational Phase 2, Phase 3 53230-10-7 4046
50
tannic acid Approved Phase 3 1401-55-4

Interventional clinical trials:

(show top 50) (show all 162)
# Name Status NCT ID Phase Drugs
1 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate Recruiting NCT04351191 Phase 4 Hydroxychloroquine Sulfate Regular dose;Hydroxychloroquine Sulfate Loading Dose;Chloroquine;Placebo
2 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate Recruiting NCT04346667 Phase 4 Hydroxychloroquine Sulfate Regular dose;Hydroxychloroquine Sulfate Loading Dose;Chloroquine;Placebo
3 A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection Recruiting NCT04252885 Phase 4 Lopinavir and Ritonavir Tablets;Arbidol
4 Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia Recruiting NCT04355637 Phase 4 Inhaled budesonide
5 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial Recruiting NCT04405999 Phase 4 Bromhexine Hydrochloride
6 An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia. Recruiting NCT04255017 Phase 4 Abidol hydrochloride;Oseltamivir;Lopinavir/ritonavir
7 A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment Recruiting NCT04384380 Phase 4 Hydroxychloroquine Sulfate 200 MG [Plaquenil]
8 A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure. Recruiting NCT04326920 Phase 4 Sargramostim
9 Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome Recruiting NCT04341493 Phase 4 Nitazoxanide 500 MG;Hydroxychloroquine
10 Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide Recruiting NCT04406246 Phase 4 Nitazoxanide 500Mg Oral Tablet
11 Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes Not yet recruiting NCT04341935 Phase 4 Linagliptin;Insulin regimen
12 Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial Not yet recruiting NCT04394377 Phase 4 Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed;Group 2: control group with enoxaparin 40mg/d
13 The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study Not yet recruiting NCT04286503 Phase 4 Carrimycin;lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate;basic treatment
14 Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial Completed NCT04244591 Phase 2, Phase 3 methylprednisolone therapy
15 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection Recruiting NCT04421027 Phase 3 Baricitinib;Placebo
16 The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients Recruiting NCT04321616 Phase 2, Phase 3 Hydroxychloroquine;Remdesivir
17 An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area Recruiting NCT04320238 Phase 3 recombinant human interferon Alpha-1b;thymosin alpha 1
18 A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection Recruiting NCT04282902 Phase 3 pirfenidone
19 The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Lahore, Pakistan Recruiting NCT04347382 Phase 3 Honey;Nigella Sativa / Black Cumin;Placebos
20 A Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate Severity Recruiting NCT04361253 Phase 3
21 COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III) Recruiting NCT04327401 Phase 3 Dexamethasone
22 Protective Role of Inhaled Steroids for Covid-19 Infection Recruiting NCT04331054 Phase 3 2: Usual practice + SYMBICORT RAPIHALER
23 A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome Recruiting NCT04330638 Phase 3 Anakinra;Siltuximab;Tocilizumab
24 Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo Recruiting NCT04334928 Phase 3 Emtricitabine/tenofovir disoproxil;Hydroxychloroquine;Placebo: Emtricitabine/tenofovir disoproxil Placebo;Placebo: Hydroxychloroquine
25 Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial Recruiting NCT04366063 Phase 2, Phase 3
26 Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial Recruiting NCT04381858 Phase 3 Plasma from COVID-19 convalescent patient;Human immunoglobulin
27 An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC "Farmzashita" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19 Active, not recruiting NCT04347031 Phase 2, Phase 3 Mefloquine;Hydroxychloroquine
28 An Open Randomized Study of the Effectiveness of the Drug Dalargin for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19) Active, not recruiting NCT04346693 Phase 3
29 ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection Enrolling by invitation NCT04326426 Phase 3 Tradipitant;Placebo
30 Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial Not yet recruiting NCT04397328 Phase 3 Hydroxychloroquine;Placebo
31 A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe Not yet recruiting NCT04373733 Phase 3 Favipiravir;Hydroxychloroquine;Azithromycin;Zinc Sulfate
32 Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19- A Cluster Randomized Controlled Trial (SHARP COVID-19 RCT) Not yet recruiting NCT04342156 Phase 3 Hydroxychloroquine Sulfate 200 milligram (mg) Tab
33 Efficacy of Convalescent Plasma for the Treatment of Severe SARS-CoV-2 Infection: A Randomized, Open Label Clinical Trial Not yet recruiting NCT04391101 Phase 3 Convalescent plasma
34 Randomized Multicenter Study Evaluating the Efficacy of Azithromycin and Hydroxychloroquine in the Prevention of SARS-CoV-2 Infection in the Hospital Population Exposed to Virus Suspended NCT04344379 Phase 3 hydroxychloroquine;azithromycin;hydroxychloroquine placebo
35 WU 352: Open-label, Randomized Controlled Trial of Hydroxychloroquine Alone or Hydroxychloroquine Plus Azithromycin or Chloroquine Alone or Chloroquine Plus Azithromycin in the Treatment of SARS CoV-2 Infection Suspended NCT04341727 Phase 3 Hydroxychloroquine Sulfate;Azithromycin;Chloroquine Sulfate
36 Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia Terminated NCT04345861 Phase 2, Phase 3 Hydroxychloroquine + placebo;hydroxychloroquine + azithromycin
37 An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection Completed NCT04276688 Phase 2 Lopinavir/ritonavir;Ribavirin;Interferon Beta-1B
38 The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease Recruiting NCT04385199 Phase 2
39 A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection Recruiting NCT04349098 Phase 2 Selinexor
40 COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma Recruiting NCT04357106 Phase 2
41 Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial. Recruiting NCT04348695 Phase 2 Ruxolitinib plus simvastatin
42 Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) Recruiting NCT04399889 Phase 1, Phase 2
43 Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia Recruiting NCT04358783 Phase 2
44 Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus Recruiting NCT04276896 Phase 1, Phase 2
45 A Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 Infection Recruiting NCT04356690 Phase 2 Etoposide
46 Double-blind, Placebo-controlled Clinical Trial of the Use of Colchicine for the Management of Patients With Mild and Severe SARS-Cov2 Infection Recruiting NCT04367168 Phase 2 Colchicine;Placebo oral tablet
47 COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study) Recruiting NCT04363437 Phase 2 Colchicine;Usual Care
48 Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial Recruiting NCT04357782 Phase 1, Phase 2 L-ascorbic acid
49 Hydroxychloroquine for Outpatients With Confirmed COVID-19 Recruiting NCT04342169 Phase 2 Hydroxychloroquine;Placebo oral tablet
50 Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19 Recruiting NCT04407182 Phase 2

Search NIH Clinical Center for Coronavirus Infectious Disease

Sources

Genetic Tests for Coronavirus Infectious Disease

About this section
Sources

Anatomical Context for Coronavirus Infectious Disease

About this section

MalaCards organs/tissues related to Coronavirus Infectious Disease:

40
Lung, Testes, T Cells, Heart, Kidney, Liver, Neutrophil
Sources

Publications for Coronavirus Infectious Disease

About this section

Articles related to Coronavirus Infectious Disease:

(show top 50) (show all 998)
# Title Authors PMID Year
1
Differential virological and immunological outcome of severe acute respiratory syndrome coronavirus infection in susceptible and resistant transgenic mice expressing human angiotensin-converting enzyme 2. 61 54
19297479 2009
2
Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. 61 54
17974127 2007
3
Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. 54 61
15838797 2005
4
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. 61
32228222 2020
5
Being a front-line dentist during the Covid-19 pandemic: a literature review. 61
32341913 2020
6
Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19). 61
32387389 2020
7
Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review. 61
32450165 2020
8
Seizures associated with coronavirus infections. 61
32416567 2020
9
The Novel Coronavirus - Latest Findings. 61
32363726 2020
10
The After Diagnosis Head and Neck cancer-specific Patient Concerns Inventory (HaNC-AD) as a pre-treatment preparation aid during the COVID-19 pandemic. 61
32338298 2020
11
New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. 61
32361161 2020
12
A picture of the covid-19 impact on IVIRMA fertility treatment clinics in Spain and Italy. 61
32451301 2020
13
Letter: Strategies for Prevention and Control of 2019 Novel Coronavirus Infection Among Medical Staff. 61
32277757 2020
14
The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. 61
32283144 2020
15
The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic. 61
32360010 2020
16
A Case of Coronavirus Infection Incidentally Found on FDG PET/CT Scan. 61
32433168 2020
17
Evidence for Use or Disuse of Renin-Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder. 61
32351121 2020
18
The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. 61
32464367 2020
19
The Role of Human Coronavirus Infection in Pediatric Acute Gastroenteritis. 61
32433226 2020
20
Surveillance and Testing for Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, March 2016-March 2019. 61
32568049 2020
21
Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. 61
32437679 2020
22
Advances in the relationship between coronavirus infection and cardiovascular diseases. 61
32428835 2020
23
Cardiovascular Consequences and Considerations of Coronavirus Infection - Perspectives for the Cardiothoracic Anesthesiologist and Intensivist During the Coronavirus Crisis. 61
32349897 2020
24
Clinical Features and Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) in a Single-Center Study in Shanghai, China. 61
32174128 2020
25
Spatial association between primary Middle East respiratory syndrome coronavirus infection and exposure to dromedary camels in Saudi Arabia. 61
32112508 2020
26
Novel Coronavirus Infection (COVID-19) in Children Younger Than One Year: A Systematic Review of Symptoms, Management and Outcomes. 61
32557789 2020
27
Use of 4 robotic arms performing Senhance® robotic surgery may reduce the risk of coronavirus infection to medical professionals during COVID-19. 61
32536465 2020
28
Global Comparison of Changes in the Number of Test-Positive Cases and Deaths by Coronavirus Infection (COVID-19) in the World. 61
32570833 2020
29
Analysis of 2019 novel coronavirus infection and clinical characteristics of outpatients: An epidemiological study from a fever clinic in Wuhan, China. 61
32544281 2020
30
[Clinical analysis of 150 cases of 2019 novel coronavirus infection in Nanyang City, Henan Province]. 61
32295322 2020
31
Host Gene Expression of Macrophages in Response to Feline Coronavirus Infection. 61
32526950 2020
32
Novel Coronavirus Infection in Febrile Infants Aged 60 Days and Younger. 61
32527752 2020
33
Biologic agents in psoriasis: our experience during coronavirus infection. 61
32516447 2020
34
Advances in the relationship between coronavirus infection and coagulation function. 61
32209889 2020
35
Critical Concerns About 2019 Novel Coronavirus Infection in Pediatric Population. 61
32376103 2020
36
Clinically suspected myocarditis in the course of coronavirus infection. 61
32338758 2020
37
Endocrine and metabolic link to coronavirus infection. 61
32242089 2020
38
Conquest of COVID-19. Publish it to Death? 61
32480419 2020
39
Hematological features of persons with COVID-19. 61
32528042 2020
40
Development of an automatic integrated gene detection system for novel Severe acute respiratory syndrome-related coronavirus (SARS-CoV 2). 61
32543298 2020
41
COVID-19 in persons with haematological cancers. 61
32332856 2020
42
Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action. 61
32350686 2020
43
A health observation app for COVID-19 symptom tracking integrated with personal health records: Proof of concept and practical use. 61
32568728 2020
44
Characteristics of the initial patients hospitalized for COVID-19: a single-center report. 61
32490641 2020
45
The red half moon nail sign: a novel manifestation of Coronavirus infection. 61
32535979 2020
46
Facebook, Instagram, Reddit and TikTok: a proposal for health authorities to integrate popular social media platforms in contingency planning amid a global pandemic outbreak. 61
32519085 2020
47
Cardiac Surgery in Canada During the COVID-19 Pandemic: A Guidance Statement From the Canadian Society of Cardiac Surgeons. 61
32299752 2020
48
Update Alert: Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers. 61
32515983 2020
49
The stress-inducible molecular chaperone GRP78 as potential therapeutic target for Coronavirus infection. 61
32535155 2020
50
Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection? 61
32532069 2020
Sources

Variations for Coronavirus Infectious Disease

About this section
Sources

Expression for Coronavirus Infectious Disease

About this section
Search GEO for disease gene expression data for Coronavirus Infectious Disease.
Sources

Pathways for Coronavirus Infectious Disease

About this section

Pathways related to Coronavirus Infectious Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Measles 36
Show member pathways
 12.47 TMPRSS2 IL6 IFNB1 IFNA1 CLEC4M
2
Tuberculosis 36
11.81 IL6 IFNB1 IFNA1 CLEC4M
3
Innate Lymphoid Cells Differentiation 64
11.4 CD8A CD4 CCR6
4
all-trans-Retinoic Acid Mediated Apoptosis 63
11 IL6 IFNB1 IFNA1
5
Dendritic Cells Developmental Lineage Pathway 64
10.79 IL6 IFNB1 CD8A CD4
6
Cytokines and Inflammatory Response 1
10.59 IL6 IFNB1 CD4
Sources

GO Terms for Coronavirus Infectious Disease

About this section

Cellular components related to Coronavirus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 SERPINA3 SCARA3 MBL2 IL6 IFNB1 IFNA1
2 extracellular region GO:0005576 9.4 TMPRSS2 SERPINA3 MBL2 IL6 IFNB1 IFNA1

Biological processes related to Coronavirus Infectious Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.77 IFNB1 IFNA1 CLEC4M CD8A CD4
2 viral entry into host cell GO:0046718 9.67 DPP4 CLEC4M ACE2
3 angiotensin maturation GO:0002003 9.48 ACE2 ACE
4 positive regulation of viral entry into host cell GO:0046598 9.46 TMPRSS2 CD4
5 negative regulation of lipid storage GO:0010888 9.43 IL6 CRP
6 opsonization GO:0008228 9.4 MBL2 CRP
7 T cell activation GO:0042110 9.33 DPP4 CD8A CD4
8 neutrophil mediated immunity GO:0002446 9.32 IL6 ACE
9 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.26 ACE2 ACE
10 humoral immune response GO:0006959 9.26 IL6 IFNB1 IFNA1 CCR6
11 acute-phase response GO:0006953 8.92 SERPINA3 MBL2 IL6 CRP

Molecular functions related to Coronavirus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 exopeptidase activity GO:0008238 9.26 ACE2 ACE
2 virus receptor activity GO:0001618 9.26 DPP4 CLEC4M CD4 ACE2
3 peptidyl-dipeptidase activity GO:0008241 9.16 ACE2 ACE
4 dipeptidyl-peptidase activity GO:0008239 8.8 DPP4 ACE2 ACE
Sources

Sources for Coronavirus Infectious Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....